REG - Solvonis Therapeutic - Positive progress on European Patent Application

Solvonis TherapeuticsAnnouncement

26/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ0614Ca&default-theme=true

RNS Number : 0614C  Solvonis Therapeutics PLC  26 March 2025

 26 March 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Positive progress on European Patent Application for the AWKN-SDN-14 programme

 

Solvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company
co-developing therapeutics for mental health disorders, is pleased to report a
positive development in the intellectual property position of the AWKN-SDN-14
programme (the "Programme"), its collaboration with Awakn Life Sciences Corp.
("Awakn").  The collaboration is focused on developing next-generation
medicine for the treatment of trauma-related mental health disorders, such as
Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13
million adults in the U.S. and which the Company estimates affects 20 million
in the US, the UK, and other key EU markets.

Following the Company's announcement on 22 March 2025 regarding preclinical
progress and the appointment of Evotec SE to lead in-vitro testing, the
European Patent Office (the "EPO") has confirmed that the claims under
European Patent Application No. 22730070.4, titled "Therapeutic Aminoindane
Compounds and Compositions", are considered allowable with no objections.

This application is one of two patent families underpinning the Programme's
intellectual property portfolio and specifically covers key compound classes
being advanced through preclinical development. It represents the European leg
of a broader international patent strategy for the Programme, with protection
also being pursued in other key jurisdictions, including the United States.

In line with standard EPO procedure, the patent examiner has requested a minor
amendment to the description to reflect the scope of the allowed claims.
Subject to this formality, the application is expected to proceed to grant.

This development provides strong validation of the novelty and inventiveness
of the Programme's core compounds and further strengthens its intellectual
property position across Europe.

Anthony Tennyson, CEO of Solvonis Therapeutics, commented: "This positive news
from the European Patent Office is a strong validation of the scientific and
commercial potential of the AWKN-SDN-14 programme. Robust intellectual
property is a critical pillar of our and Awakn's strategy, and this progress
represents an important step forward as we continue to advance our pipeline
toward clinical development across key markets."

 

Enquiries:

Solvonis Therapeutics plc, Anthony Tennyson, CEO & Executive Director,
Email: anthony@solvonis.com

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) | Guy McDougall
(Sales)

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on
developing intellectual property related to the treatment of mental health and
substance use disorders, and co-developing therapeutics for mental health
disorders. Solvonis' mission is to improve outcomes for individuals suffering
from mental health disorders, with an initial focus on trauma-related mental
health conditions, such as PTSD. PTSD affected approximately 13 million adults
in the U.S. in 2020, with the Company estimating a current affected population
of 20 million across the U.S., UK, and key EU markets.

www.solvonis.com (http://www.solvonis.com) | LinkedIn
(http://www.linkedin.com/company/solvonis) | X (formerly Twitter)
(https://x.com/SolvonisTx)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPUCCWUPAUBA